GlassScriptPhysician profile
Elizabeth Kaufman
NPI 1114599545
$9,968.97
in general payments reported to CMS, 2019-2025
32 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $2,919 · 2023: $2,690 · 2024: $2,250 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,061 · Education: $63.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,060.97 |
| Education | $63.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,756.98 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $713.35 | 2022-2024 | Zeposia |
| Celgene Corporation | $566.46 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $553.32 | 2021-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $537.60 | 2021-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $442.17 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $347.46 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $228.73 | 2022-2024 | |
| Madrigal Pharmaceuticals | $221.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $218.81 | 2021-2023 | Pancreaze |
| Intercept Pharmaceuticals, INC. | $216.41 | 2021-2024 | Ocaliva |
| Redhill Biopharma INC. | $207.29 | 2021-2023 | Aemcolo, Talicia |
| Janssen Scientific Affairs, LLC | $195.90 | 2022-2023 | Stelara |
| Aimmune Therapeutics, INC. | $184.64 | 2024-2025 | Zenpep |
| Lucid Diagnostics INC. | $180.06 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $179.98 | 2021-2025 | Eohilia, Gattex, Entyvio |
| Nestle Healthcare Nutrition INC. | $179.18 | 2021-2023 | |
| Intra-Sana Laboratories | $163.31 | 2021-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Merck Sharp & Dohme LLC | $129.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $123.84 | 2021 | |
| Lilly USA, LLC | $114.43 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $107.69 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $89.15 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $84.54 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $73.49 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $35.51 | 2022 | |
| Mallinckrodt Hospital Products INC. | $25.90 | 2024 | Terlivaz |
| Ethicon US, LLC | $25.31 | 2022 | |
| Ironwood Pharmaceuticals, INC | $21.64 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $16.67 | 2025 | Rebyota |
| Braintree Laboratories, INC. | $14.71 | 2023 | Suflave, Sutab |
| Pharmacosmos Therapeutics INC. | $14.22 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.